Loading...
•
Dec 31, 2021
DexCom Q4 2021 Earnings Report
Reported financial results for the fourth quarter and fiscal year ended December 31, 2021.
Key Takeaways
DexCom reported a 23% increase in worldwide revenue for Q4 2021, reaching $698.2 million. However, GAAP operating income decreased significantly, and the company experienced a GAAP net loss of $19.4 million, or $0.20 per diluted share.
Revenue grew 23% to $698.2 million compared to the same quarter of the prior year.
U.S. revenue grew 15% and international revenue grew 54%.
GAAP operating income was $0.6 million, a decrease of 1,820 basis points compared to Q4 2020.
GAAP net loss was $19.4 million, or $0.20 per diluted share, compared to GAAP net income of $355.2 million in Q4 2020.
Revenue by Segment
Revenue by Geographic Location
Forward Guidance
The company is reiterating guidance for fiscal year 2022 revenue, and establishing guidance for full year Non-GAAP Gross Profit Margin, Non-GAAP Operating Margin, and Adjusted EBITDA Margin to the following levels:
Positive Outlook
- Revenue of approximately $2.82 - 2.94 billion (15-20% growth)
- Non-GAAP Gross Profit Margin of approximately 65%
- Non-GAAP Operating Margin of approximately 16%
- Adjusted EBITDA Margin of approximately 25%
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...